5/17/2013

AstraZeneca plans to advance its three cancer drug candidates into Phase III trials. Set to advance are moxetumomab pasudotox for patients with hairy cell leukemia, selumetinib for patients with KRAS-positive nonsmall-cell lung cancer, and olaparib for patients with platinum-sensitive relapsed ovarian cancer. The firm also plans to double the number of drugs in its late-stage pipeline and submit three regulatory applications by 2016.

Related Summaries